Elevance Health Beats Q1 EPS, Raises Full-Year Guidance Despite $935M CMS Accrual

summarizeSummary

Elevance Health reported strong Q1 results, beating adjusted EPS expectations and raising its full-year adjusted EPS guidance, despite recording a $935 million accrual related to a CMS notice.

check_boxKey Events

• Exceeded Q1 Earnings Expectations

  Elevance Health reported first-quarter 2026 adjusted diluted EPS of $12.58, surpassing expectations and reflecting strong operating results.

• Raised Full-Year Guidance

  The company increased its full-year 2026 adjusted diluted EPS guidance to at least $26.75, citing underlying business strength and improved visibility.

• Significant CMS Accrual

  A $935 million accrual was recorded in operating expense, representing the estimated potential exposure for historical Medicare Advantage risk adjustment data related to a February 27, 2026 CMS notice.

• Capital Returned to Shareholders

  Elevance Health returned $1.5 billion to shareholders in Q1 2026, including $1.1 billion in share repurchases and $376 million in quarterly dividends.

auto_awesomeAnalysis

Elevance Health reported first-quarter results that exceeded expectations, driven by strong operating performance and non-recurring investment income. The company raised its full-year adjusted diluted EPS guidance, signaling increased confidence in its underlying business strength and medical cost management initiatives. While a significant $935 million accrual was recorded for a potential CMS matter, the company's ability to still raise guidance suggests this impact is being managed within their financial outlook. The substantial capital return to shareholders through repurchases and dividends further underscores financial health and commitment to shareholder value. Investors should monitor the resolution of the CMS matter and the company's continued execution on its revised guidance.